Physician profile
Robert Alan Paul
NPI 1902858566
$10,970.32
in general payments reported to CMS, 2019-2025
51 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $1,995 · 2021: $1,828 · 2022: $1,561 · 2023: $1,434 · 2024: $1,400 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,928.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,842.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,089.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $930.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $769.44 | 2019-2025 | Jardiance |
| Pfizer INC. | $608.09 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $602.01 | 2019-2024 | Qelbree, Xyosted, Qelbree |
| Glaxosmithkline, LLC. | $480.82 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $402.51 | 2021-2025 | |
| Amgen INC. | $398.89 | 2019-2024 | Repatha, Otezla |
| Astellas Pharma US INC | $394.48 | 2020-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $324.10 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $312.89 | 2020-2022 | |
| Allergan, INC. | $272.33 | 2019-2020 | |
| Abbott Laboratories | $244.75 | 2021-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $237.13 | 2021-2023 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.